the characteristics that contribute to the performance and safety of innovative nanotechnology-based treatments through the data acquired by the measurements. The facility may be used by the nanotechnology researchers from both business and academia fields to test new prototypes and develop new processes for their research projects.
Dr Zahra Rattray, lecturer in Translational Pharmaceutics at Strathclyde Institute of Pharmacy and Biomedical Sciences and Chancellor’s research fellow, discussed the applications of nanotechnology in the healthcare sector. He said, “Nanotechnology for health is a rapidly growing sector, as seen with vaccines developed during the Covid-19 pandemic and the increased use of nanotechnologies in cancer diagnostics and therapies. We are excited about the opportunities the MMS will create with the proposal partners, the Laboratory of the Government Chemist, the Medicines Discovery Catapult and the Centre for Process Innovation, as well as the wider UK and international nanotechnology communities, in addressing the challenges faced in nanomedicine design.”
